Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1220 results
September 2016
-
Media Release
Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine
ARISE, first pivotal Phase III study of AMG 334 (erenumab) in episodic migraine prevention, met primary endpoint, showing a statistically significant reduction in monthly migraine days vs placebo… -
Media Release
Sandoz invites young entrepreneurs to enter Sandoz HACk, a global competition to help solve healthcare access challenges
Despite significant advances made by modern medicine, universal access to healthcare is still arguably the single largest unmet medical need Sandoz "HACk" - Healthcare Access Challenge - is… -
Media Release
Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions
Ilaris® (canakinumab) is the first and only US FDA-approved biologic treatment for patients with TRAPS, HIDS/MKD and FMF disease These three simultaneous approvals conducted under FDA… -
Media Release
Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia® in untreated adult ALK+ NSCLC patients
In a Phase III clinical study, Zykadia® extended progression-free survival (PFS) when compared with standard chemotherapy, including maintenance Novartis is moving forward with global… -
Media Release
Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs
Results published in the New England Journal of Medicine demonstrate that KAF156 shows activity against blood and liver stages of malaria parasites, including artemisinin-resistant parasites… -
Media Release
Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients
New analysis of PARADIGM-HF data shows that among patients who had been hospitalized for heart failure, those on Entresto reported higher relative health-related quality of life (HRQL) scores… -
Media Release
Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients
EXPAND study data presented at ECTRIMS show that treatment with BAF312 (siponimod) reduced the risk of three-month confirmed disability progression by 21% vs placebo in people with secondary… -
Media Release
New Novartis data presented at ECTRIMS show benefit of Gilenya® on patient disability progression at 10 years
ACROSS study shows that patients with relapsing remitting multiple sclerosis (RRMS) continuously treated with Gilenya® (fingolimod) had significantly lower disability progression compared to those… -
Media Release
Novartis presents new positive data at EHMTIC showing AMG 334 significantly reduces monthly migraine days in chronic migraine
Detailed results from Phase II study in chronic migraine prevention showed patients on AMG 334 (erenumab) were significantly more likely to experience a 50% or more reduction in monthly migraine… -
Media Release
Novartis Foundation showcases progress in leprosy elimination programs at 19th International Leprosy Congress
Emerging evidence from first 18 months of LPEP program demonstrates operational feasibility integrating single-dose rifampicin into routine control programs in 6 countries Retrospective… -
Media Release
New Novartis point of care Niji(TM) System may provide earlier diagnosis of severe allergic asthma and faster treatment decisions
NijiTM System, Total IgE Test delivers results rapidly, allowing for quick in-office diagnosis of IgE-mediated allergic disorders and faster treatment decisions Point of care in office…